Open Access

Evaluation of a novel type of imaging probe based on a recombinant bivalent mini-antibody construct for detection of CD44v6-expressing squamous cell carcinoma

  • Authors:
    • Anna-Karin Haylock
    • Diana Spiegelberg
    • Anja C. Mortensen
    • Ram K. Selvaraju
    • Johan Nilvebrant
    • Olof Eriksson
    • Vladimir Tolmachev
    • Marika V. Nestor
  • View Affiliations

  • Published online on: December 14, 2015     https://doi.org/10.3892/ijo.2015.3290
  • Pages: 461-470
  • Copyright: © Haylock et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We have developed the CD44v6-targeting human bivalent antibody fragment AbD19384, an engineered recombinant human bivalent Fab antibody formed via dimerization of dHLX (synthetic double helix loop helix motif) domains, for potential use in antibody-based molecular imaging of squamous cell carcinoma in the head and neck region. This is a unique construct that has, to the best of our knowledge, never been assessed for molecular imaging in vivo before. The objective of the present study was to evaluate for the first time the in vitro and in vivo binding properties of radio-iodinated AbD19384, and to assess its utility as a targeting agent for molecular imaging of CD44v6-expressing tumors. Antigen specificity and binding properties were assessed in vitro. In vivo specificity and biodistribution of 125I-AbD19384 were next evaluated in tumor-bearing mice using a dual-tumor setup. Finally, AbD19384 was labeled with 124I, and its imaging properties were assessed by small animal PET/CT in tumor bearing mice, and compared with 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG). In vitro studies demonstrated CD44v6-specific binding with slow off-rate for AbD19384. A favorable biodistribution profile was seen in vivo, with tumor-specific uptake. Small animal PET/CT images of 124I-AbD19384 supported the results through clearly visible high CD44v6-expressing tumors and faintly visible low expressing tumors, with superior imaging properties compared to 18F-FDG. Tumor-to-blood ratios increased with time for the conjugate (assessed up to 72 h p.i.), although 48 h p.i. proved best for imaging. Biodistribution and small-animal PET studies demonstrated that the recombinant Fab-dHLX construct AbD19384 is a promising tracer for imaging of CD44v6 antigen expression in vivo, with the future aim to be used for individualized diagnosis and early detection of squamous cell carcinomas in the head and neck region. Furthermore, this proof-of-concept research established the feasibility of using recombinant Fab-dHLX constructs for in vivo imaging of tumor biomarkers.

References

1 

Chames P, Van Regenmortel M, Weiss E and Baty D: Therapeutic antibodies: Successes, limitations and hopes for the future. Br J Pharmacol. 157:220–233. 2009. View Article : Google Scholar : PubMed/NCBI

2 

Olafsen T and Wu AM: Antibody vectors for imaging. Semin Nucl Med. 40:167–181. 2010. View Article : Google Scholar : PubMed/NCBI

3 

Hoeben BA, Kaanders JH, Franssen GM, Troost EG, Rijken PF, Oosterwijk E, van Dongen GA, Oyen WJ, Boerman OC and Bussink J: PET of hypoxia with 89Zr-labeled cG250-F(ab′)2 in head and neck tumors. J Nucl Med. 51:1076–1083. 2010. View Article : Google Scholar : PubMed/NCBI

4 

Willkomm P, Bender H, Bangard M, Decker P, Grünwald F and Biersack HJ: FDG PET and immunoscintigraphy with 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma. J Nucl Med. 41:1657–1663. 2000.PubMed/NCBI

5 

Khawli LA, Alauddin MM, Hu P and Epstein AL: Tumor targeting properties of indium-111 labeled genetically engineered Fab' and F(ab')2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody. Cancer Biother Radiopharm. 18:931–940. 2003. View Article : Google Scholar

6 

Bradbury AR, Sidhu S, Dübel S and McCafferty J: Beyond natural antibodies: The power of in vitro display technologies. Nat Biotechnol. 29:245–254. 2011. View Article : Google Scholar : PubMed/NCBI

7 

Nilvebrant J, Kuku G, Björkelund H and Nestor M: Selection and in vitro characterization of human CD44v6-binding antibody fragments. Biotechnol Appl Biochem. 59:367–380. 2012. View Article : Google Scholar

8 

Reichert JM and Dhimolea E: The future of antibodies as cancer drugs. Drug Discov Today. 17:954–963. 2012. View Article : Google Scholar : PubMed/NCBI

9 

Pack P and Plückthun A: Miniantibodies: Use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli. Biochemistry. 31:1579–1584. 1992. View Article : Google Scholar : PubMed/NCBI

10 

Eisenberg D, Wilcox W, Eshita SM, Pryciak PM, Ho SP and DeGrado WF: The design, synthesis, and crystallization of an alpha-helical peptide. Proteins. 1:16–22. 1986. View Article : Google Scholar : PubMed/NCBI

11 

Orian-Rousseau V: CD44, a therapeutic target for metastasising tumours. Eur J Cancer. 46:1271–1277. 2010. View Article : Google Scholar : PubMed/NCBI

12 

Pluckthun A and Pack P: New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology. 3:83–105. 1997. View Article : Google Scholar : PubMed/NCBI

13 

Nestor M, Sundström M, Anniko M and Tolmachev V: Effect of cetuximab in combination with alpha-radioimmunotherapy in cultured squamous cell carcinomas. Nucl Med Biol. 38:103–112. 2011. View Article : Google Scholar : PubMed/NCBI

14 

Stenberg J, Spiegelberg D, Karlsson H and Nestor M: Choice of labeling and cell line influences interactions between the Fab fragment AbD15179 and its target antigen CD44v6. Nucl Med Biol. 41:140–147. 2014. View Article : Google Scholar

15 

Hunter WM and Greenwood FC: Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature. 194:495–496. 1962. View Article : Google Scholar : PubMed/NCBI

16 

Larkin EA, Stiles BG and Ulrich RG: Inhibition of toxic shock by human monoclonal antibodies against staphylococcal entero-toxin B. PLoS One. 5:e132532010. View Article : Google Scholar

17 

Kalinke U, Krebber A, Krebber C, Bucher E, Plückthun A, Zinkernagel RM and Hengartner H: Monovalent single-chain Fv fragments and bivalent miniantibodies bound to vesicular stomatitis virus protect against lethal infection. Eur J Immunol. 26:2801–2806. 1996. View Article : Google Scholar : PubMed/NCBI

18 

Haylock AK, Spiegelberg D, Nilvebrant J, Sandström K and Nestor M: In vivo characterization of the novel CD44v6-targeting Fab fragment AbD15179 for molecular imaging of squamous cell carcinoma: A dual-isotope study. EJNMMI Res. 4:112014. View Article : Google Scholar : PubMed/NCBI

19 

Portulano C, Paroder-Belenitsky M and Carrasco N: The Na+/I symporter (NIS): Mechanism and medical impact. Endocr Rev. 35:106–149. 2014. View Article : Google Scholar :

20 

Holechek MJ: Glomerular filtration: an overview. Nephrol Nurs J. 30:285–290; quiz 291-282. 2003.PubMed/NCBI

21 

Rudnick SI and Adams GP: Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm. 24:155–161. 2009. View Article : Google Scholar : PubMed/NCBI

22 

Schreiber AB, Libermann TA, Lax I, Yarden Y and Schlessinger J: Biological role of epidermal growth factor-receptor clustering. Investigation with monoclonal anti-receptor antibodies. J Biol Chem. 258:846–853. 1983.PubMed/NCBI

23 

Truong MT, Erasmus JJ, Munden RF, Marom EM, Sabloff BS, Gladish GW, Podoloff DA and Macapinlac HA: Focal FDG uptake in mediastinal brown fat mimicking malignancy: A potential pitfall resolved on PET/CT. AJR Am J Roentgenol. 183:1127–1132. 2004. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

February 2016
Volume 48 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Haylock, A., Spiegelberg, D., Mortensen, A.C., Selvaraju, R.K., Nilvebrant, J., Eriksson, O. ... Nestor, M.V. (2016). Evaluation of a novel type of imaging probe based on a recombinant bivalent mini-antibody construct for detection of CD44v6-expressing squamous cell carcinoma. International Journal of Oncology, 48, 461-470. https://doi.org/10.3892/ijo.2015.3290
MLA
Haylock, A., Spiegelberg, D., Mortensen, A. C., Selvaraju, R. K., Nilvebrant, J., Eriksson, O., Tolmachev, V., Nestor, M. V."Evaluation of a novel type of imaging probe based on a recombinant bivalent mini-antibody construct for detection of CD44v6-expressing squamous cell carcinoma". International Journal of Oncology 48.2 (2016): 461-470.
Chicago
Haylock, A., Spiegelberg, D., Mortensen, A. C., Selvaraju, R. K., Nilvebrant, J., Eriksson, O., Tolmachev, V., Nestor, M. V."Evaluation of a novel type of imaging probe based on a recombinant bivalent mini-antibody construct for detection of CD44v6-expressing squamous cell carcinoma". International Journal of Oncology 48, no. 2 (2016): 461-470. https://doi.org/10.3892/ijo.2015.3290